Alnylam Pharma (ALNY) – Major News
-
Alnylam Pharma (ALNY) Tops Q4 EPS by 49c; offers guidance
-
Alnylam Pharma (ALNY) Tops Q3 EPS by $3.06
-
Alnylam Pharma (ALNY) Misses Q2 EPS by 10c
-
Alnylam Pharma (ALNY) Tops Q1 EPS by 62c, Beats on Revenue; Offers FY23 Guidance
-
Alnylam Pharma (ALNY) Tops Q4 EPS by 46c
-
Alnylam Pharma (ALNY) Tops Q3 EPS by 15c, Misses on Revenue, Offers FY22 Revenue Guidance
-
Alnylam Pharma (ALNY) Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy Met Primary Endpoint
-
Alnylam Pharma (ALNY) Misses Q2 EPS by 42c
-
Alnylam Pharma (ALNY) Tops Q1 EPS by 35c
-
Alnylam Pharma (ALNY) Misses Q4 EPS by 13c
-
Alnylam Pharma (ALNY) Misses Q3 EPS by 15c
-
Alnylam Pharma (ALNY) Tops Q2 EPS by 30c
-
Alnylam Pharma (ALNY) Tops Q1 EPS by 11c
-
Alnylam Pharma (ALNY) Tops Q4 EPS by 16c
-
Alnylam Pharma (ALNY) Tops Q3 EPS by 8c
-
Alnylam Pharma (ALNY) Tops Q2 EPS by 7c
-
Alnylam Pharma (ALNY) Tops Q1 EPS by 37c
-
Alnylam Pharma (ALNY) Tops Q4 EPS by 24c
-
Alnylam Pharma (ALNY) Tops Q3 EPS by 54c
-
Alnylam Pharma (ALNY) Misses Q2 EPS by 16c
-
Alnylam Pharma (ALNY) Tops Q1 EPS by 65c
-
Alnylam (ALNY), Regeneron (REGN) Announce Pact on RNAi Therapeutics Focused on Ocular and CNS Diseases; Regeneron to Make Payment of $400M Upfront and Purchase Stock at $90/Share
-
Alnylam Pharma (ALNY) ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria Met Primary Efficacy Endpoint
-
Alnylam Pharma (ALNY) Tops Q4 EPS by 19c
-
Alnylam Pharma (ALNY) Misses Q3 EPS by 42c
-
Alnylam Pharma (ALNY) Patisiran (Onpattro) Approved by FDA
-
Alnylam Pharma (ALNY) Tops Q2 EPS by 16c
-
Alnylam Pharma (ALNY) Posts Smaller-than-Expected Q1 Loss
-
Alnylam Pharma (ALNY) Tops Q4 EPS by 19c, Beats on Revenues
-
Alnylam Pharma (ALNY) Granted FDA Breakthrough Therapy Designation for Patisiran
-
Alnylam Pharma (ALNY) Tops Q3 EPS by 21c
-
Sanofi, Alnylam Pharmaceuticals (ALNY) Announces APOLLO Phase 3 Study of Patisiran Met Primary Efficacy Endpoint and All Secondary Endpoints
-
Alnylam Pharma (ALNY) Tops Q2 EPS by 15c
-
Alnylam Pharma (ALNY) Tops Q1 EPS by 1c
-
Alnylam Pharma (ALNY) Tops Q4 EPS by 2c
-
Alnylam Pharma (ALNY) Misses Q3 EPS by 7c
-
Alnylam Pharma (ALNY) Misses Q3 EPS by 7c
-
Alnylam Pharma (ALNY) to Discontinue Development of Revusiran; Decision Will Not Affect Patisiran
-
Alnylam Pharma (ALNY) Tops Q2 EPS by 19c
-
Alnylam Pharma (ALNY) Misses Q1 EPS by 16c
-
Alnylam Pharma (ALNY) Misses Q4 EPS by 11c
-
Alnylam Pharma (ALNY) Reports In-Line Q3 EPS
-
Alnylam Pharma (ALNY) Misses Q2 EPS by 10c
-
Alnylam Pharma (ALNY) Tops Q1 EPS by 4c
-
Alnylam Pharma (ALNY) Tops Q4 EPS by 32c
-
Alnylam Pharma (ALNY) Tops Q3 EPS by 5c
-
Alnylam Pharmaceuticals, Inc. (ALNY) Misses Q2 EPS by 7c
-
Alnylam Pharmaceuticals, Inc. (ALNY) Posts Q1 Loss of 39c/Share
-
Alnylam Pharmaceuticals, Inc. (ALNY) Misses Q4 EPS by 6c
-
Alnylam Pharmaceuticals (ALNY) Surges on Deal to Acquire Merck's (MRK) Sirna Therapeutics for $175M+
Back to ALNY Stock Lookup